Hey I am on Medial • 4m
I invested in three biotech IPOs during the COVID bubble. All of them had "revolutionary technology" and "massive TAM" stories. All three are down 70%+ from IPO price. The problem with biotech investing is that retail investors can't properly evaluate the technical claims or regulatory pathways. We're relying on management projections, which are always optimistic for IPOs. What concerns me about Molbio is the timing - they could have gone public during their COVID revenue peak but didn't. Why now? Likely because they've seen their peak and want to cash out while the story still sounds good. Hard pass from me.
Finding my self 😶�... • 5m
🤯Lenskart is planning to go public by the end of 2025, targeting a valuation of $7-8 billion. The company aims to raise $750 million to $1 billion through its IPO. Despite reporting a minor loss of ₹10 crore on revenues of ₹5,427 crore in FY24, Lens
See MoreData Science Enthusi... • 1y
RECESSION WARNING: US Leading Economic Index® (LEI) is down 14.7% from this economic cycle peak. In the last 65 years, such a drop happened only during recessions. Index takes into account, US labor market data, manufacturing sector data, building
See MoreDownload the medial app to read full posts, comements and news.